Pharmaceuticals

Preeclampsia Drugs Market Growth Projection: Expected to Surpass $2.37 Billion by 2030 at 11.8% CAGR

February 18, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the preeclampsia drugs market from 2026–2035 with trusted insights from The Business Research Company

How is the Preeclampsia Drugs Market size predicted to change over the forecast window of 2026–2035?

The preeclampsia drugs market size has seen swift expansion in recent times. It is set to increase from $1.37 billion in 2025 to $1.52 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.6%. The historical growth can be linked to factors such as limited awareness surrounding preeclampsia management, a dependence on conventional treatments, the unavailability of advanced monitoring technologies, inadequate hospital infrastructure, and low investment in maternal health medications.

The preeclampsia drugs market is projected to experience swift expansion over the coming years. This market is set to reach $2.37 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.8%. The anticipated increase during the forecast period stems from factors such as improvements in drug formulations, the broadening of healthcare infrastructure, a greater need for outpatient maternal services, the incorporation of digital health technologies, and enhanced research and development in precision medicine targeting pregnancy complications. Key developments expected within this period involve the increasing prevalence of preeclampsia among expectant mothers, the creation of new antihypertensive medications, a heightened emphasis on monitoring both maternal and fetal health, the expansion of distribution channels through hospital pharmacies and specialized clinics, and the use of combination treatments for severe instances.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13025&type=smp

Which Drivers Are Contributing To The Expansion Of The Preeclampsia Drugs Market?

The increasing incidence of diabetes among pregnant women is anticipated to fuel the expansion of the preeclampsia drug market. Diabetes is a long-term metabolic condition identified by elevated blood glucose levels. Preeclampsia represents a hazardous pregnancy complication involving high blood pressure and damage to organs. Metformin, a preeclampsia medicine, is widely administered to pregnant women experiencing preterm preeclampsia. For example, in June 2024, reports from the National Health Service, a UK-based government department, indicated that in 2023, the NHS discovered over 549,000 additional individuals in England at risk of developing type 2 diabetes. This raised the total number of people diagnosed with non-diabetic hyperglycemia, or pre-diabetes, and registered with a GP to 3,615,330. This figure marks a considerable rise compared to 3,065,825 in 2022, reflecting an increase of nearly 20%. Consequently, the growing number of diabetes cases among pregnant women will propel the preeclampsia drug market.

What Segment Categories Are Covered In The Preeclampsia Drugs Market?

The preeclampsia drugs market covered in this report is segmented –

1) By Type: Mild Preeclampsia, Severe Preeclampsia

2) By Treatment: Medication to Lower Hypertension (B.P), Corticosteroids, Anticonvulsants Medication

3) By Route of Administration: Oral, Parenteral, Other Route of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels

5) By End-User: Hospitals, Specialty Clinics, Diagnostic Centers, Other End-Users

Subsegments:

1) By Mild Preeclampsia: Blood Pressure Management

2) By Severe Preeclampsia: Antihypertensive Medications, Magnesium Sulfate Therapy

How Are New Market Trends Shaping The Landscape Of The Preeclampsia Drugs Market?

Leading companies in the preeclampsia medicine market are concentrating on developing advanced therapies, such as small interfering RNA (siRNA) treatments, to address significant unmet medical needs through novel mechanisms of action. Investigational siRNA therapies represent a class of medicines engineered to suppress or deactivate specific genes responsible for causing a disease, thereby offering a targeted approach to treatment. For instance, in March 2023, Comanche Biopharma Corp., a US-based biopharmaceutical firm, announced that the Food and Drug Administration (FDA) had cleared an investigational new drug (IND) application for CBP-4888, Comanche’s unique siRNA treatment for preeclampsia. CBP-4888 is an siRNA therapy administered subcutaneously that reduces the synthesis of soluble fms-like tyrosine kinase-1 (sFLT1) in the placenta. The primary cause of preeclampsia is the placenta’s overproduction of the sFLT1 protein, which then enters the mother’s circulation. This therapy, CBP-4888, has the potential to alleviate preeclampsia symptoms, including high blood pressure and organ damage, and may facilitate the safe extension of pregnancy.

Which Major Industry Participants Are Leading The Preeclampsia Drugs Market Growth?

Major companies operating in the preeclampsia drugs market are AbbVie Inc., Pfizer Inc., Johnson & Johnson Co, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline PLC, Takeda Pharmaceuticals Company Limited, Eli Lilly and Company, Boehringer Ingelheim Group, Viatris Inc., Teva Pharmaceutical Industries Ltd., Baxter International Inc., Otsuka Pharmaceutical Co. Ltd., Mallinckrodt Pharmaceuticals Limited, Union Chimique Belge SA, Kyowa Kirin Co Ltd, Comanche Biopharma Corp

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/preeclampsia-drugs-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Preeclampsia Drugs Market?

North America was the largest region in the preeclampsia drugs market in 2025. The regions covered in the preeclampsia drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Preeclampsia Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13025&type=smp

Browse Through More Reports Similar to the Global Preeclampsia Drugs Market 2026, By The Business Research Company

Preeclampsia Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/preeclampsia-drugs-global-market-report

Fertility Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/fertility-drugs-global-market-report

Epilepsy Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/epilepsy-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795